Comment on: "Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma"
Minerva Urol Nephrol
.
2023 Jun;75(3):401-403.
doi: 10.23736/S2724-6051.23.05354-5.
Authors
Vincenzo Asero
1
,
Carlo M Scornajenghi
1
,
Wojciech Krajewski
2
,
Tomasz Szydełko
2
,
Bartosz Malkiewicz
2
,
Łukasz Nowak
2
,
Andrea Gallioli
3
,
Satvir Basran
4
,
Benjamin I Chung
4
,
Francesco Del Giudice
5
4
;
European Association of Urology (EAU) - Young Academic Urologist (YAU) Working Group
Affiliations
1
Department of Maternal-Infant and Urological Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy.
2
Department of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland.
3
Department of Urology, Fundacio Puigvert, Barcelona, Spain.
4
Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.
5
Department of Maternal-Infant and Urological Sciences, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy -
[email protected]
.
PMID:
37221829
DOI:
10.23736/S2724-6051.23.05354-5
No abstract available
Publication types
Comment
MeSH terms
Animals
Carcinoma, Transitional Cell*
Combined Modality Therapy
Mitomycin
Urinary Bladder Neoplasms*
Substances
Mitomycin